Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011335 · ClinicalTrials.gov registry record · Phase 1
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
A Phase 1 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT01011335 is a Phase 1 study that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 176 participants.
The verdict
NCT01011335, a Phase 1 study, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Monovalent rAT
- BIOLOGICAL Monovalent rLukS-PV
- BIOLOGICAL Bivalent rLukS-PV / rAT
- BIOLOGICAL Placebo with adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011335
The ClinicalTrials.gov registry entry for NCT01011335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01011335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011335 about?
NCT01011335 is a clinical study titled "Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial". This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune respo...
What is the current status of trial NCT01011335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01011335?
The interventions under investigation include: Placebo (BIOLOGICAL), Monovalent rAT (BIOLOGICAL), Monovalent rLukS-PV (BIOLOGICAL), Bivalent rLukS-PV / rAT (BIOLOGICAL), Placebo with adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01011335?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.